ST Renfu announced that its controlling subsidiary, Yichang Renfu, recently received a Drug Clinical Trial Approval Notice for Hydromorphone Hydrochloride Tablets from the National Medical Products Administration, granting permission to conduct a randomized controlled clinical study for the treatment of moderate to severe postoperative pain in adults. The drug is a Class 3 chemical drug and has not yet been approved for marketing in China. To date, Yichang Renfu has invested approximately 5.4 million yuan in the project. The company stated that it must complete clinical studies before applying for production and marketing, and the research and approval process involves long cycles and multiple steps with uncertainties, reminding investors to be aware of the risks.
Humanwell Healthcare Group Co LtdSubsidiary received clinical trial approval for a new drug, indicating progress in R&D pipeline.
Directly received clinical trial approval for Hydromorphone Hydrochloride Tablets.